|[June 12, 2014]
Research and Markets: Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/73pt8x/neuro_endocrine)
has announced the addition of the "Neuro
Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014"
report to their offering.
This report provides comprehensive information on the therapeutic
development for Neuro Endocrine (Carcinoid) Carcinoma, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
It also reviews key players involved in the therapeutic development for
Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage
and discontinued projects.
Drug profiles/rcords featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
The report provides a snapshot of the global therapeutic landscape of
Neuro Endocrine (Carcinoid) Carcinoma
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
The report reviews key players involved in the therapeutics
development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all
their major and minor projects
The report summarizes all the dormant and discontinued pipeline
F. Hoffmann-La Roche Ltd.
Progenics Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Vascular Biogenics Ltd.
Advanced Accelerator Applications
Foresee Pharmaceuticals, LLC
For more information visit http://www.researchandmarkets.com/research/73pt8x/neuro_endocrine
[ Back To Technology News's Homepage ]